Date of Award
8-2024
Document Type
Dissertation
Degree Name
Doctor of Medical Science (DMSc)
First Advisor
Jason Brumitt
Abstract
Uncontrolled moderate to severe asthma is a disease process that persists despite the maximum therapy of either oral corticosteroids OCS or inhaled corticosteroids (ICS) and long-acting B2 agonists (LABA)1,4 . Severe asthma affects less than 10% of the patients with asthma.5 Asthma can be differentiated as type 2 (Th2) asthma which is characterized by inflammation driven by T-helper (Th) type-2 cells, and non-type 2 asthma, which encompasses all other forms of asthma that do not involve type 2 immune responses. About 50%-70% of the population is diagnosed with type 2 asthma and most patients with severe asthma have at least one Th2 inflammatory trait2 . Both Th2 and non-type 2 asthma, which make up the remaining 30%-50% cause symptoms of wheezing, mucus production, and exacerbations; specific to Type 2 asthma is allergic symptoms, response to allergens, and response to biologic therapies targets to Th2 asthma.
Recommended Citation
Liaw, Alex; Chang, William; Adelman, Travis; Guffey, Josh; and Brumitt, Jason, "A Scoping Review: Comparison of Tezepelumab and Mepolizumab in the Treatment of Persistent Severe Asthma" (2024). Doctor of Medical Science (DMSc). 45.
https://digitalcommons.georgefox.edu/dmsc/45